Status:

COMPLETED

The Clinical and Economic Impact of Pharmacogenomic Testing for Tamoxifen Metabolism in Postmenopausal Women Receiving Tamoxifen for Prevention of Recurrent Breast Cancer

Lead Sponsor:

Medco Health Solutions, Inc.

Collaborating Sponsors:

Laboratory Corporation of America

International Business Machines (IBM)

Conditions:

Breast Neoplasms

Tamoxifen

Eligibility:

FEMALE

50+ years

Brief Summary

This study will assess the impact of CYP450 2D6 genotype pharmacogenetic testing and the corresponding prescribing impact for postmenopausal women using tamoxifen in a patient care setting for prevent...

Detailed Description

Tamoxifen is a non-steroidal hormonal drug with weak estrogen agonist and potent estrogen antagonist actions. The liver CYP450 metabolic enzyme systems are responsible for metabolizing tamoxifen (the ...

Eligibility Criteria

Inclusion

  • Patient currently has a pharmacy benefit with Medco for an enrolled client
  • Patient has a adjudicated tamoxifen pharmacy claims within the last six months
  • Patient is still taking tamoxifen to prevent recurrent breast cancer
  • Patient is a natural postmenopausal women 50 years of age or older
  • Patient signs consent
  • Patient is willing to provide sample for genetic testing
  • Physician managing tamoxifen therapy is willing to order pharmacogenetic test

Exclusion

  • Patient is male
  • Patient is under 50 years old
  • Patient has previous history of CYP450 2D6 testing
  • Patient is no longer taking tamoxifen
  • Patient refuses to sign consent
  • Patient wishes to no longer participate after testing
  • Patient's physician refuses to order pharmacogenetic test

Key Trial Info

Start Date :

October 1 2007

Trial Type :

OBSERVATIONAL

Allocation :

ACTUAL

End Date :

January 1 2009

Estimated Enrollment :

184 Patients enrolled

Trial Details

Trial ID

NCT00830973

Start Date

October 1 2007

End Date

January 1 2009

Last Update

October 14 2009

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Robert Epstein

Franklin Lakes, New Jersey, United States, 07417

The Clinical and Economic Impact of Pharmacogenomic Testing for Tamoxifen Metabolism in Postmenopausal Women Receiving Tamoxifen for Prevention of Recurrent Breast Cancer | DecenTrialz